Bempedoic Acid Reduces Major Adverse Cardiovascular Events for Statin-Intolerant Patients.
作者信息
Cunningham John M, Kiazand Mehrshid
机构信息
Division of Hospital Medicine, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health at San Antonio, San Antonio, TX, USA.
Department of Medicine, University of Pittsburg Medical Center Mercy HospitalSchool of Medicine, Pittsburgh, PA, USA.
出版信息
J Gen Intern Med. 2024 Jun;39(8):1536-1538. doi: 10.1007/s11606-024-08704-y.
Abstract
摘要
相似文献
1
Bempedoic Acid Reduces Major Adverse Cardiovascular Events for Statin-Intolerant Patients.贝派地酸可降低他汀类药物不耐受患者的主要不良心血管事件风险。
J Gen Intern Med. 2024 Jun;39(8):1536-1538. doi: 10.1007/s11606-024-08704-y.
2
Bempedoic Acid: A Review in Cardiovascular Risk Reduction in Statin-Intolerant Patients.贝派地酸：关于降低他汀类药物不耐受患者心血管风险的综述
Am J Cardiovasc Drugs. 2025 Jan;25(1):7-16. doi: 10.1007/s40256-024-00714-9. Epub 2025 Jan 23.
3
Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis.高危他汀不耐受患者使用苯扎贝特酸的心血管结局风险：系统评价和荟萃分析。
Future Cardiol. 2024;20(11-12):639-650. doi: 10.1080/14796678.2024.2388478. Epub 2024 Aug 14.
4
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.在不能耐受他汀类药物的高胆固醇血症患者中，添加苯扎贝特酸与依折麦布联合治疗的疗效和安全性：一项随机、安慰剂对照研究。
Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12.
5
Bempedoic acid and cardiovascular outcomes.贝匹地酸与心血管结局。
Drug Ther Bull. 2023 Nov 29;61(12):180. doi: 10.1136/dtb.2023.000054.
6
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.贝匹地酸降低 LDL 胆固醇的安全性和有效性。
N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917.
7
In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo.在他汀类药物不耐受的患有或有心血管疾病风险的成年人中，贝匹地酸在中位数为 41 个月时降低了 MACE。
Ann Intern Med. 2023 Jul;176(7):JC75. doi: 10.7326/J23-0044. Epub 2023 Jul 4.
8
Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR Outcomes trial.在CLEAR Outcomes试验中，接受贝派地酸治疗的有和没有他汀类药物相关肌肉症状的患者的特征和结局
J Clin Lipidol. 2025 Mar-Apr;19(2):337-347. doi: 10.1016/j.jacl.2024.12.014. Epub 2024 Dec 25.
9
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.贝特帕酸联合依折麦布固定剂量复方制剂在最大耐受他汀治疗的高胆固醇血症和高 CVD 风险患者中的应用。
Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29.
10
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.贝匹地酸对比安慰剂联合最大耐受他汀类药物治疗对心血管疾病高危患者的低密度脂蛋白胆固醇的影响：CLEAR Wisdom 随机临床试验。
JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585.
引用本文的文献
1
Bis-Iridoid Glycosides and Triterpenoids from and Their Potential as Inhibitors of ACC1 and ACL.来自[具体来源未给出]的双环烯醚萜苷和三萜类化合物及其作为ACC1和ACL抑制剂的潜力。
Molecules. 2024 Dec 18;29(24):5980. doi: 10.3390/molecules29245980.
本文引用的文献
1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.贝匹地酸在他汀类药物不耐受患者中的心血管结局。
N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4.
2
Prevalence of statin intolerance: a meta-analysis.他汀类药物不耐受的流行率：一项荟萃分析。
Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015.
3
Statin treatment non-adherence and discontinuation: clinical implications and potential solutions.他汀类药物治疗的不依从性和停药：临床影响及潜在解决方案。
Curr Pharm Des. 2014;20(40):6314-24. doi: 10.2174/1381612820666140620162629.
Zotero 插件